Recap Of Thursday’s Biotech Catalysts – End of The Day Summary
Cyclerion Therapeutics (NASDAQ:CYCN) announced positive topline data from its clinical study of CY6463 for the treatment of Cognitive…
Akerna Shares Dip 53%, Here’s 78 Biggest Movers From Yesterday
Gainers
Revelation Biosciences, Inc. (NASDAQ: REVB) surged 77.4% to close at $1.11 on Thursday after jumping 27% on Wednesday. Revelation Biosciences recently announced completion of dosing for Phase 1b CLEAR clinical study of REVTx-99b for the treatment of allergic rhinitis.
Dow Jumps 150 Points; Icosavax Shares Plunge
U.S. stocks turned higher toward the end of trading, with the Dow Jones gaining around 150 points on Wednesday.
U.S. Stocks Turn Negative; 2U Shares Spike Higher
U.S. stocks pared gains midway through trading, with all the three major indices turning lower on Wednesday.
The Daily Biotech Pulse: Eli Lilly Modifies COVID-19 Treatment Pact, Oyster Point Outlines Restructuring Plan, Icosavax Posts Interim RSV Vaccine Data
Here's a roundup of top developments in the biotech space over the last 24 hours:
Why U.S. Stocks Are Trading Higher, GDP Report And More
U.S. stocks traded higher this morning, with the Dow Jones gaining around 180 points on Wednesday.
Icosavax Shares Plummet Following Interim Results From Initial-Stage RSV Vaccine Study
Icosavax (NASDAQ: ICVX) announced interim results from its Phase 1/1b clinical trial of IVX-121, respiratory syncytial virus (RSV) F antigen, in young and older adults.
The Phase 1/1b clinical trial is designed to evaluate the safety and immunogenicity of three dose levels of IVX-121.